Role of Imaging in Prostate Cancer

Overview

Journal PET Clin

Specialty Radiology

Date 2010 Feb 18

PMID 20161047

Citations 5

Authors

Hossein Jadvar

Abass Alavi

Affiliations

Soon will be listed here.

Citing Articles

Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer.

Zacharias N, McCullough C, Shanmugavelandy S, Lee J, Lee Y, Dutta P Sci Rep. 2017; 7(1):16159.

PMID: 29170516 PMC: 5701017. DOI: 10.1038/s41598-017-16327-z.

Influence of (11)C-choline PET/CT on radiotherapy planning in prostate cancer.

Lopez E, Lazo A, Gutierrez A, Arregui G, Nunez I, Sacchetti A Rep Pract Oncol Radiother. 2015; 20(2):104-12.

PMID: 25859399 PMC: 4338287. DOI: 10.1016/j.rpor.2014.11.008.

Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake.

Schuster D, Taleghani P, Nieh P, Master V, Amzat R, Savir-Baruch B Am J Nucl Med Mol Imaging. 2013; 3(1):85-96.

PMID: 23342303 PMC: 3545368.

Role of ¹¹C-choline positron emission tomography/computed tomography in evaluating patients affected by prostate cancer with suspected relapse due to prostate-specific antigen elevation.

Bertagna F, Abuhilal M, Bosio G, Simeone C, Rossini P, Pizzocaro C Jpn J Radiol. 2011; 29(6):394-404.

PMID: 21786095 DOI: 10.1007/s11604-011-0570-1.

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.

Jadvar H J Nucl Med. 2010; 52(1):81-9.

PMID: 21149473 PMC: 3012154. DOI: 10.2967/jnumed.110.077941.

References

Fossa S, Dearnaley D, Law M, Gad J, Newling D, Tveter K . Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann Oncol. 1992; 3(5):361-6. DOI: 10.1093/oxfordjournals.annonc.a058207. View

Yu K, Hricak H . Imaging prostate cancer. Radiol Clin North Am. 2000; 38(1):59-85, viii. DOI: 10.1016/s0033-8389(05)70150-0. View

Lee C, Oesterling J . Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am. 1997; 24(2):389-94. DOI: 10.1016/s0094-0143(05)70385-2. View

Sella A, Konichezky M, Flex D, Sulkes A, Baniel J . Low PSA metastatic androgen- independent prostate cancer. Eur Urol. 2000; 38(3):250-4. DOI: 10.1159/000020289. View

Lin D, Noteboom J, Blumenstein B, Ellis W, Lange P, Vessella R . Serum percent free prostate-specific antigen in metastatic prostate cancer. Urology. 1998; 52(3):366-71. DOI: 10.1016/s0090-4295(98)00240-4. View

Timme T, Satoh T, Tahir S, Wang H, Teh B, Butler E . Therapeutic targets for metastatic prostate cancer. Curr Drug Targets. 2003; 4(3):251-61. DOI: 10.2174/1389450033491127. View

Small E . Prostate cancer, Incidence, management and outcomes. Drugs Aging. 1998; 13(1):71-81. DOI: 10.2165/00002512-199813010-00007. View

McMurtry C, McMurtry J . Metastatic prostate cancer: complications and treatment. J Am Geriatr Soc. 2003; 51(8):1136-42. DOI: 10.1046/j.1532-5415.2003.51367.x. View

Drelichman A, Decker D, Al-Sarraf M, VAITKEVICIUS V, MUZ J . Computerized bone scan. A potentially useful technique to measure response in prostatic carcinoma. Cancer. 1984; 53(5):1061-5. DOI: 10.1002/1097-0142(19840301)53:5<1061::aid-cncr2820530508>3.0.co;2-3. View

10.

Culig Z, Klocker H, Bartsch G, Hobisch A . Androgen receptors in prostate cancer. Endocr Relat Cancer. 2002; 9(3):155-70. DOI: 10.1677/erc.0.0090155. View

11.

Elgamal A, Holmes E, Su S, Tino W, Simmons S, Peterson M . Prostate-specific membrane antigen (PSMA): current benefits and future value. Semin Surg Oncol. 2000; 18(1):10-6. DOI: 10.1002/(sici)1098-2388(200001/02)18:1<10::aid-ssu3>3.0.co;2-v. View

12.

Boccon-Gibod L . [Prostate-specific antigen or PSA. Facts and probabilities]. Presse Med. 1995; 24(32):1471-2. View

13.

Ploch N, Brawer M . How to use prostate-specific antigen. Urology. 1994; 43(2 Suppl):27-35. DOI: 10.1016/0090-4295(94)90215-1. View

14.

Bauer K, Figg W, HAMILTON J, Jones E, Premkumar A, Steinberg S . A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer. Clin Cancer Res. 1999; 5(9):2324-9. View

15.

Culig Z, Hobisch A, HITTMAIR A, Cronauer M, Radmayr C, Bartsch G . Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy. Drugs Aging. 1997; 10(1):50-8. DOI: 10.2165/00002512-199710010-00005. View

16.

Dotan Z . Bone imaging in prostate cancer. Nat Clin Pract Urol. 2008; 5(8):434-44. DOI: 10.1038/ncpuro1190. View

17.

Lofters A, Juffs H, Pond G, Tannock I . "PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer. J Urol. 2002; 168(6):2516-20. DOI: 10.1016/S0022-5347(05)64180-8. View

18.

Harisinghani M, Barentsz J, Hahn P, Deserno W, Tabatabaei S, van de Kaa C . Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003; 348(25):2491-9. DOI: 10.1056/NEJMoa022749. View

19.

Carlin B, Andriole G . The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 2000; 88(12 Suppl):2989-94. DOI: 10.1002/1097-0142(20000615)88:12+<2989::aid-cncr14>3.3.co;2-h. View

20.

Haseman M, Rosenthal S, Polascik T . Capromab Pendetide imaging of prostate cancer. Cancer Biother Radiopharm. 2000; 15(2):131-40. DOI: 10.1089/cbr.2000.15.131. View